Reteplase labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
{| | {| | ||
|[[File:Rets1.JPG| | |[[File:Rets1.JPG|400px|thumb]] | ||
|} | |} | ||
| Line 14: | Line 14: | ||
{| | {| | ||
|[[File:Reteplase.JPG| | |[[File:Reteplase.JPG|400px|thumb]] | ||
|} | |} | ||
| Line 20: | Line 20: | ||
{| | {| | ||
|[[File:Rets2.jpg| | |[[File:Rets2.jpg|400px|thumb]] | ||
|} | |} | ||
| Line 26: | Line 26: | ||
{| | {| | ||
|[[File:Rets3.jpg| | |[[File:Rets3.jpg|400px|thumb]] | ||
|} | |} | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = | accessdate = }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 15:16, 4 March 2014
| Reteplase |
|---|
| Retavase® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Reteplase |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
LABELS AND PACKAGES
Package Label - Principal Display Panel – Full Kit Carton
 |
Package Label - Principal Display Panel – Full Kit Vial
 |
Package Label - Principal Display Panel – Half Kit Carton
 |
Package Label - Principal Display Panel – Half Kit Vial
 |
References
Adapted from the FDA Package Insert.